Literature DB >> 25777582

Cannabinoid replacement therapy (CRT): Nabiximols (Sativex) as a novel treatment for cannabis withdrawal.

D J Allsop1,2, N Lintzeris2,3, J Copeland4, A Dunlop5,6, I S McGregor1.   

Abstract

Cannabis is a common recreational drug that is generally considered to have low addictive potential. However, an increasing number of cannabis users are seeking treatment for dependence on the drug. There is interest in using agonist (substitution) pharmacotherapies to treat cannabis dependence and here we outline a novel approach involving a buccal spray (nabiximols) that contains tetrahydrocannabinol (THC) and cannabidiol (CBD). We review recent research with nabiximols and highlight findings relevant to clinical practice.
© 2015 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25777582     DOI: 10.1002/cpt.109

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  16 in total

1.  Cannabidiol regulates behavioural alterations and gene expression changes induced by spontaneous cannabinoid withdrawal.

Authors:  Francisco Navarrete; Auxiliadora Aracil-Fernández; Jorge Manzanares
Journal:  Br J Pharmacol       Date:  2018-05-03       Impact factor: 8.739

Review 2.  Screening Medications for the Treatment of Cannabis Use Disorder.

Authors:  L V Panlilio; Z Justinova; J M Trigo; B Le Foll
Journal:  Int Rev Neurobiol       Date:  2016-03-10       Impact factor: 3.230

3.  Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial.

Authors:  Tom P Freeman; Chandni Hindocha; Gianluca Baio; Natacha D C Shaban; Emily M Thomas; Danica Astbury; Abigail M Freeman; Rachel Lees; Sam Craft; Paul D Morrison; Michael A P Bloomfield; Dominic O'Ryan; Jane Kinghorn; Celia J A Morgan; Ali Mofeez; H Valerie Curran
Journal:  Lancet Psychiatry       Date:  2020-07-28       Impact factor: 27.083

4.  Novel behavioral assays of spontaneous and precipitated THC withdrawal in mice.

Authors:  Kristen R Trexler; Sara R Nass; Molly S Crowe; Joshua D Gross; Margaret S Jones; Austin W McKitrick; David P Siderovski; Steven G Kinsey
Journal:  Drug Alcohol Depend       Date:  2018-07-07       Impact factor: 4.492

Review 5.  Cannabinoids and Epilepsy.

Authors:  Evan C Rosenberg; Richard W Tsien; Benjamin J Whalley; Orrin Devinsky
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

6.  Medical Marijuana-Opportunities and Challenges.

Authors:  Qing-Song Liu
Journal:  Biochem Pharmacol (Los Angel)       Date:  2016-05-25

Review 7.  Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders.

Authors:  Francisco Navarrete; María Salud García-Gutiérrez; Ani Gasparyan; Amaya Austrich-Olivares; Jorge Manzanares
Journal:  Front Pharmacol       Date:  2021-05-20       Impact factor: 5.810

Review 8.  Cannabis based medicines and cannabis dependence: A critical review of issues and evidence.

Authors:  Anne K Schlag; Chandni Hindocha; Rayyan Zafar; David J Nutt; H Valerie Curran
Journal:  J Psychopharmacol       Date:  2021-02-17       Impact factor: 4.153

Review 9.  Progress toward pharmacotherapies for cannabis-use disorder: an evidence-based review.

Authors:  Jan Copeland; Izabella Pokorski
Journal:  Subst Abuse Rehabil       Date:  2016-05-03

10.  Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial.

Authors:  Jose M Trigo; Alexandra Soliman; Lena C Quilty; Benedikt Fischer; Jürgen Rehm; Peter Selby; Allan J Barnes; Marilyn A Huestis; Tony P George; David L Streiner; Gregory Staios; Bernard Le Foll
Journal:  PLoS One       Date:  2018-01-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.